Design, Synthesis, and Activity of a Novel Series of Pyridazine-Based ALK5 Inhibitors
Authors:
- 23 October 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 15 (11) , 1925-1932
Abstract
ALK5 inhibitors represent an attractive therapeutic approach for the treatment of a variety of pathologies, including cancer and fibrosis. Herein, we report the design and in vitro characterization of a novel series of ALK5 modulators featuring a 4,6-disubstituted pyridazine core. A knowledge-based scaffold-hopping exploration was initially conducted on a restricted set of heteroaromatic cores using available ligand- and structure-based information. The most potent structurally novel hit compound 2A was subsequently subjected to a preliminary optimization for the inhaled delivery, applying physicochemical criteria aimed at minimizing systemic exposure to limit the risk of adverse side effects. The resulting inhibitors showed a marked boost in potency against ALK5 and in vitro ADME properties, potentially favoring lung retention. The optimized hits 20 and 23 might thus be considered promising starting points for the development of novel inhaled ALK5 inhibitors.Keywords
This publication has 27 references indexed in Scilit:
- Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitorsBioorganic Chemistry, 2024
- Targeting transforming growth factor beta signaling in metastatic osteosarcomaJournal of Bone Oncology, 2023
- Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibitionToxicology and Applied Pharmacology, 2022
- Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology AgentsACS Medicinal Chemistry Letters, 2018
- Safer approaches to therapeutic modulation of TGF-β signaling for respiratory diseasePharmacology & Therapeutics, 2018
- Targeting TGF-β Signaling in CancerTrends in Cancer, 2017
- TGF‐β Signaling in CancerJournal of Cellular Biochemistry, 2016
- From libraries to candidate: The discovery of new ultra long-acting dibasic β2-adrenoceptor agonistsBioorganic & Medicinal Chemistry Letters, 2012
- Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973